Search the MBS

Whole body prostate-specific membrane antigen PET study performed for
the initial staging of intermediate to high-risk prostate adenocarcinoma, for a
previously untreated patient who is considered suitable for locoregional
therapy with curative intent

Applicable once per lifetime (R)

Bulk bill incentive

Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,201.30

(See para IN.0.17, IN.0.19 of explanatory notes to this Category)

• Previous - Item 61560
• Next - Item 61564

Whole body prostate-specific membrane antigen PET study performed for
the restaging of recurrent prostate adenocarcinoma, for a patient who:
(a) has undergone prior locoregional therapy; and
(b) is considered suitable for further locoregional therapy to determine
appropriate therapeutic pathways and timing of treatment initiation

Applicable twice per lifetime (R)

Bulk bill incentive

Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,201.30

(See para IN.0.17, IN.0.19 of explanatory notes to this Category)

• Previous - Item 61563
• Next - Item 61565

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy. (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61564
• Next - Item 61571

Whole body FDG PET study, for the further primary staging of  patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent. (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61565
• Next - Item 61575

Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent. (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61571
• Next - Item 61577

Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61575
• Next - Item 61598

Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61577
• Next - Item 61604

Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61598
• Next - Item 61610

Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes (R).

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

• Previous - Item 61604
• Next - Item 61612

Whole body FDG PET study for the initial staging of eligible cancer types, for a patient who is considered suitable for active therapy, if:

(a) the eligible cancer type is:

(i) a rare or uncommon cancer (less than 12 cases per 100,000 persons per year); and

(ii) a typically FDG‑avid cancer; and

(b) there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient

Applicable once per cancer diagnosis (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.17, IN.0.19 of explanatory notes to this Category)

• Previous - Item 61610
• Next - Item 61620